FORWARD II ASCO Abstract | IMGN Message Board Posts

ImmunoGen, Inc.

  IMGN website

  • Investor Village needs your help. We are working hard to improve your user experience
    by upgrading the site so it works better on the latest mobile devices, browsers, O/S, etc. Because costs exceed our normal operating budget, we are asking everyone, including "lurkers," to support our efforts.

    Click this PayPal link to make a one-time contribution in whatever amount you think is fair.

    Or click here to support us with a monthly contribution, starting as low as $2.50 per month.

    Payments can be made directly via PayPal or Credit Card with no need to create an Investor Village account. Cancel any time.

IMGN   /  Message Board  /  Read Message



Rec'd By
Authored By
Minimum Recs
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board
Msg  49458 of 49886  at  5/15/2019 8:53:10 PM  by



This is the same set of patients, but notice that the ORR is better now at 56% than the 50% achieved at interim.
In FORWARD II's combination with Bevacizumab, Mirv. S. is meant to replace the chemo component typically used with Bev. Note that FORWARD II doesn't have the same restrictions on enrollment as FORWARD I or AURELIA without requirements for FR-alpha expression or number of prior therapies; here was 3 the median number of therapies (1-8 possible) vs a maximum of 2 for AURELIA.
They achieved parity with AURELIA results overall with a sicker population and fewer side effects but were markedly superior for patients who have had fewer prior therapies and have med/high FR-alpha expression and/or were Bev. naive.

     e-mail to a friend      printer-friendly     add to library      
| More
Recs: 2     Views: 272
Previous Message  Next Message   Post Message   Post a Reply return to message boardtop of board

About Us  •  Contact Us  •  Follow Us on Twitter  •  Members Directory  •  Help Center  •  Advertise
Not a member yet? What are you waiting for? Create Account
Want to contribute? Support InvestorVillage by donating
© 2003-2019 All rights reserved. User Agreement
Financial Market Data provided by